Back to Search Start Over

Discovery of pyrrolo[2,1- f ][1,2,4]triazine-based inhibitors of adaptor protein 2-associated kinase 1 for the treatment of pain.

Authors :
Dzierba CD
Dasgupta B
Karageorge G
Kostich W
Hamman B
Allen J
Esposito KM
Padmanabha R
Grace J
Lentz K
Morrison J
Morgan D
Easton A
Bourin C
Browning MR
Rajamani R
Good A
Parker DD
Muckelbauer JK
Khan J
Camac D
Ghosh K
Halan V
Lippy JS
Santone KS
Denton RR
Westphal R
Bristow LJ
Conway CM
Bronson JJ
Macor JE
Source :
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents [Med Chem Res] 2023 Jun 03, pp. 1-7. Date of Electronic Publication: 2023 Jun 03.
Publication Year :
2023
Publisher :
Ahead of Print

Abstract

Adaptor protein 2-associated kinase 1 (AAK1) is a member of the Ark1/Prk1 family of serine/threonine kinases and plays a role in modulating receptor endocytosis. AAK1 was identified as a potential therapeutic target for the treatment of neuropathic pain when it was shown that AAK1 knock out (KO) mice had a normal response to the acute pain phase of the mouse formalin model, but a reduced response to the persistent pain phase. Herein we report our early work investigating a series of pyrrolo[2,1- f ][1,2,4]triazines as part of our efforts to recapitulate this KO phenotype with a potent, small molecule inhibitor of AAK1. The synthesis, structure-activity relationships (SAR), and in vivo evaluation of these AAK1 inhibitors is described.<br />Competing Interests: Conflict of interestThe authors declare no competing interests.<br /> (© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023.)

Details

Language :
English
ISSN :
1054-2523
Database :
MEDLINE
Journal :
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
Publication Type :
Report
Accession number :
37362320
Full Text :
https://doi.org/10.1007/s00044-023-03079-x